Last week, Aduhelm, a controversial new Alzheimer's drug from drugmaker Biogen, was given accelerated approval from the Food and Drug Administration, meaning that it will need to complete another trial upon public release. Now, the Centers for Medicare and Medicaid Services (CMS) needs to determine if it will cover the unproven...
